Pronota develops diagnostic devices for the early detection of conditions such as heart failure, pre-eclampsia and sepsis.
Pronota NV is developing and commercialising first-in-class diagnostics for early detection of life-threatening conditions and unmet medical needs including heart failure, pre-eclampsia and sepsis. Pronota's non-invasive, validated, diagnostics are proprietary and focused on improving quality of care for patients. Backed by a solid base of investors including GIMV, LSP, KBC Private Equity and JJDC, and a wide network of renowned key opinion leaders, Pronota is committed to making a difference in diagnosis and personalized healthcare. Pronota NV was formerly known as Peakadilly NV and changed its name to Pronota NV in November 2006. The company was founded in 2004 and is based in Zwijnaarde, Belgium.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 20, 2012 | Series C | €3.70M | 1 | — | — | Detail |
May 19, 2010 | Series B | €1.50M | 1 | — | — | Detail |
Jun 29, 2009 | Series B | $7.36M | 2 | — | — | Detail |
Aug 22, 2006 | Series A | $10.60M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Biotech Fund Flanders | — | Series C |
MedSciences Capital | — | Series B |
Baekeland Funds | — | Series B |